The significance of QT interval in drug development

British Journal of Clinical Pharmacology

Volumn 54, Issue 2, 2002, Pages 188-202

  Shah, Rashmi R ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

Astemizole; Bazett; Cisapride; Clinical trials; Dose schedules; Droperidol; Drug development; Fridericia; Grepafloxacin; Halofantrine; Metabolites; Pharmacogenetics; Pimozide; Prenylamine; QT interval; Sertindole; Stereoselectivity; Terfenadine; Terodiline

Indexed keywords

AMILORIDE; ANTIDEPRESSANT AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ASTEMIZOLE; BUPIVACAINE; CISAPRIDE; DOBUTAMINE; DROPERIDOL; GATIFLOXACIN; GREPAFLOXACIN; HALOFANTRINE; LEVACETYLMETHADOL; LUBELUZOLE; MELPERONE; MOXIFLOXACIN; NEUROLEPTIC AGENT; PIMOZIDE; PROBUCOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN ANTAGONIST; SERTINDOLE; SEVOFLURANE; TACROLIMUS; TERFENADINE; TERODILINE; THIORIDAZINE; TIAPRIDE; UNINDEXED DRUG; ZIPRASIDONE;

CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG APPROVAL; DRUG CLASSIFICATION; ELECTROCARDIOGRAPHY; HEART DEPOLARIZATION; HUMAN; INCIDENCE; LONG QT SYNDROME; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; QT INTERVAL; RISK BENEFIT ANALYSIS; RISK FACTOR; STEREOCHEMISTRY; TORSADE DES POINTES;

CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; HUMANS; LEGISLATION, DRUG; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS;

EID: 0036039326     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01627.x     Document Type: Conference Paper

References (96)

1. Genotype and severity of long QT syndrome
2. La tachycardie ventriculaire á deux foyers oppośes variable
3. Torsade de pointes due to quinidine: Observations in 31 patients
4. Clinical safety profile of sotalol in the treatment of arrhythmias
5. Sotalol, hypokalaemia, syncope, and torsade de pointes
6. Torsade de pointes. Apropos of 54 cases
7. Torsades de pointe. Apropos of 60 cases
8. Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past three decades - 1969-98
9. Use of terfenadine and contraindicated drugs
10. Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin
11. Contraindicated use of cisapride: Impact of Food and Drug Administration regulatory action
12. Electrocardiograms, high-dose antipsychotic treatment and College guidelines
13. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current
14. The effect of sildenafil on QT interval in healthy men
15. Assessment of QTc prolongations for non-cardiac-related drugs from a drug development perspective
16. Withdrawal of terodiline. A tale of two toxicities
17. Torsades de pointes occurring in association with terfenadine use
18. J & J, hit by new Propulsid warnings
19. FDA warns of interactions with Orap
20. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
21. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences
22. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome
23. Combined use of astemizole and ketoconazole resulting in torsade de pointes
24. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
25. The metabolism of antihistamines and drug interactions: The role of cytochrome P450 enzymes
26. Mechanism of the cardiotoxic actions of terfenadine
27. Effects of terfenadine and its metabolites on a delayed rectifier K + channel cloned from human heart
28. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole
29. Torsade de pointes with an antihistamine metabolite: Potassium channel blockade with desmethylastemizole
30. Propulsid limited access program allows off-label use to continue
31. Torsade de pointes after astemizole overdose
32. Cardiotoxic effect with convulsions in terfenadine overdose
33. ECG changes during haloperidol and pimozide treatment of Tourette's disorder
34. Stereoselective effects of the enantiomers of bupivacaine on the electrophysiological properties of guinea-pig papillary muscle
35. Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers
36. Mechanism of cardiotoxicity of halofantrine
37. Stereoselective halofantrine disposition and effect: Concentration-related QTc prolongation
38. Stereoselective cardiotoxic effects of terodiline
39. Basic mechanism underlying prenylamine-induced torsade de pointes: Differences between prenylamine and fendiline due to basic actions of the isomers
40. Lilly pulls out of R-fluoxetine deal
41. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function
42. Plasma levels of thioridazine and metabolites are influended by the debrisoquin hydroxylation phenotype
43. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone
44. The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine
45. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: Relationship to the CYP2D6 genotype
46. Influence of CYP2D6 genetic polymorphism on the pharmacokinetics and pharmacodynamic effects of terikalant, a new K+ channel blocker
47. + channels
48. Molecular genetics of the long QT syndrome: Two novel mutations of the KVLQT1 gene and phenotypic expression of the mutant gene in a large kindred
49. Low penetrance in the long-QT syndrome: Clinical impact
50. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs
51. Drug-induced QT prolongation in women during the menstrual cycle
52. Prolonged QT and hypertrophic cardiomyopathy in two families with 10 sudden deaths
53. Prolonged QT interval in hypertrophic and dilated cardiomyopathy in children
54. Familial hypertrophic cardiomyopathy associated with prolongation of the QT interval
55. Molecular basis of transient outward potassium current downregulation in human heart failure: A decrease in Kv4.3 mRNA correlates with a reduction in current density
56. QT interval prolongation as predictor of sudden death in patients with myocardial infarction
57. Prolongation of the QT interval and the sudden infant death syndrome
58. QT interval prolongation and mortality in type 1 diabetic patients: A 5-year cohort prospective study
59. Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes: A meta-analysis
60. Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus
61. Altered ventricular repolarization during hypoglycaemia in patients with diabetes
62. Q-T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors
63. Abnormalities of the QT interval in primary disorders of autonomic failure
64. Prolonged QTc intervals in Parkinson's disease - Relation to sudden death and autonomic dysfunction
65. Potassium channel down-regulation in heart failure
66. Severe cardiac arrhythmia on cisapride
67. Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): A meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians
68. Exploring the hidden danger of noncardiac drugs
69. The pre-clinical assessment of QT interval prolongation: A comparison of in vitro and in vivo methods
70. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: Results of an international survey
71. The assessment of potential for QT interval prolongation with new pharmaceuticals: Impact on drug development
72. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome
73. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel
74. A minK-HERG complex regulates the cardiac potassium current I (Kr)
75. Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: Present and future implications
76. QT interval prolongation by non-cardiovascular drugs: Issues and solutions for novel drug development
77. The canine Purkinje fiber: An in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis
78. The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-Iife-threatening conditions CPMP Guideline (CPMP/ICH/375/95)
79. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans
80. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects
81. Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers
82. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)
83. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome
84. The cardiac pharmacodynamics of therapeutic doses of sparfloxacin
85. Effect of signle ascending supratherapeutic doses of sparfloxacin on cardiac repolarisation (QTc interval)
86. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin
87. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia
88. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug effect from spontaneous variability
89. Torsade de pointes induced by d,l-sotalol
90. Problems of heart rate correction in assessment of drug-induced QT interval prolongation